Prot #VT3996-201: A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Project: Research project

Project Details

StatusActive
Effective start/end date2/23/182/23/21

Funding

  • CTI Clinical Trial and Consulting Services (Prot #VT3996-201)
  • Viracta Therapeutics, Inc. (Prot #VT3996-201)